REFERENCES
- Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WM, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. Am J Hypertens. 2004; 17: 154–160
- ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77: 67–75
- Topalak O, Saygili U, Soyturk M, Karaca N, Batur Y, Uslu T, Erten O. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002; 85: 108113
- Savvidou MD, Lees CC, Parra M, Hingorani AD, Nicolaides KH. Levels of C-reactive protein in pregnant women who subsequently develop preeclampsia. Br J Obstet Gynecol 2002; 109: 297–301
- Wolf M, Kettyle E, Sandler L, Ecker JL, Roberts J, Thadhani R. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001; 98: 757–762
- Ustün Y, Engin-Ustün Y, Kamaci M. Association of fibrinogen and C-reactive protein with severity of preeclampsia. Eur J Obstet Gynecol Reprod Biol Aug, 2005; 1(121)154–158
- Hwang HS, Kwon JY, Kim MA, Park YW, Kim YH. Maternal serum highly sensitive C-reactive protein in normal pregnancy and preeclampsia. Int J Gynaecol Obstet 2007; 98: 105–109
- Teran E, Escudero C, Moya W, Flores M, Vallance P, Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with preeclampsia. Int J Gynecol Obstet 2001; 75: 243–249
- Okerengwo AA, Williams AI, Ibeziako PA. Immunological studies on preeclampsia in Nigerian women. Int J Gynaecol Obstet 1990; 33: 121–125
- Tjoa ML, Van Vugt JMG, Go ATTJJ, Blankenstein MA, Oudejans CBM, Van Wijk IJ. Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. J Reprod Immun 2003; 59: 29–37
- Morán-Mendoza A, Alvarado-Luna G, Calderillo-Ruiz G, Serrano-Olvera A, López-Graniel CM, Gallardo-Rincón D. Elevated CA125 level associated with Meigs' syndrome: case report and review of the literature. Int J Gynecol Cancer 2006; 16(Suppl 1)315–318
- Epiney M, Bertossa C, Weil A, Campana A, Bischof P. CA125 production by peritoneum: in-vitro and in-vivo studies. Hum Reprod 2000; 15: 1261–1265
- Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996; 62: 384–389
- Hornstein M, Thomas PP, Gleason RE, Barbieri RL. Menstrual cyclicity of CA 125 in patients with endometriosis. Fertil Steril 1992; 58: 279–83
- Jager W, Diedrich K, Wildt L. Elevated levels of CA-125 in serum of patients suffering from ovarian hyperstimulation syndrome. Fertil Steril 1987; 48: 675–678
- Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327–1329
- Bon GG, Kenemans P, Verstraeten AA, Go S, Philipi PA, van Kamp GJ, van Geijn HP, van Vugt JM. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther 2001; 16: 166–172
- Schröcksnadel H, Daxenbichler G, Artner E, Steckel-Berger G, Dapunt O. Tumor markers in hypertensive disorders of pregnancy. Gynecol Obstet Invest 1993; 35: 204–208
- Lellé RJ, Henkel E, Leinemann D, Goeschen K. Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest 1989; 27: 137–142